The Latest Breaking News from diabetes

With weight loss and diabetes drugs in high demand and short supply, potentially dangerous counterfeits have flooded the market.

The recent announcement that China approved Novo Nordisk's Wegovy is huge. Here's why: In a national survey conducted during 2015-2019 by China’s National Health Commission, more than half of the adult population was either overweight or obese. That's a massive market that just opened up for NVO.

Researchers warned there is a ‘lack of consistent and high-quality evidence’ over the devices for people who do not have diabetes.

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy

Findings are first to provide evidence that chemical’s administration increases type 2 diabetes risk, researchers say

According to the study results published in the journal eBiomedicine, children born underweight face greater health risks if they develop obesity.

Vermont senator will grill CEO of Danish pharma giant whose drugs cost Americans 10 times more than abroad

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

The study suggests that following a specific intermittent fasting plan, such as the 5:2 intermittent fasting technique and a meal replacement diet, might help improve glycemic control among those with type 2 diabetes.

The Latino community, with a low rate of health insurance, is the most affected.

Experts suggest the findings have the potential to benefit many people in the UK.